Substance · official US FDA label
Lactulose (lactulose)
20 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for lactulose, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for lactulose, effective July 23, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for lactulose
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATIONS AND USAGE For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement. Note: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water or milk.
Warnings and precautions
WARNINGS A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H 2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO 2 as an additional safeguard may be pursued but is considered to be a redundant measure.
Side effects
ADVERSE REACTIONS Precise frequency data are not available. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia. Nausea and vomiting have been reported. To report SUSPECTED ADVERSE REACTIONS, contact Apozeal Pharmaceuticals Inc. at tel: 1-833-688-7848 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- DUPHALAC 10 g/15 ml, solution buvable en sachet
- Duphalac 10g/15 ml, solution orale
- DUPHALAC 66,5 POUR CENT, solution buvable en flacon
- Duphalac 667mg/ml, sirop
- FLORALAC 10 g/15 ml, solution buvable en sachet
- Lactulose 3,1–3,7 g/5 ml, Solution buvable
- LACTULOSE ARROW 10 g/15 ml, solution buvable en sachet-dose
- LACTULOSE BIOGARAN 10 g/15 ml, solution buvable en sachet
- LACTULOSE BIOGARAN 66,5 %, solution buvable
- LACTULOSE COOPER 66,5 %, solution buvable
- LACTULOSE FRESENIUS 670 mg/ml, solution buvable en flacon
- LACTULOSE SANDOZ 10 g, solution buvable en sachet-dose
- LACTULOSE VIATRIS 10 g/15 ml, solution buvable en sachet
- LACTULOSE VIATRIS SANTE 10 g, solution buvable en sachet-dose
- LACTULOSE ZENTIVA 10 g, solution buvable en sachet-dose
- LAEVOLAC 10 g/15 ml, solution buvable en sachet
- LAEVOLAC AROME PRUNE 10 g/15 ml, solution buvable en sachet
- MELAXIB 3,50 g/4,29 g/2,14 g pour 10 g, pâte orale en sachet (in French)
Combined with other substances
- MELAXOSE, pâte orale en pot (in French)
Combined with other substances
- TRANSULOSE, gelée orale en pot (in French)
Combined with other substances
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.